Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.
Liapis K, Papadopoulos V, Vrachiolias G, Galanopoulos AG, Papoutselis M, Papageorgiou SG, Diamantopoulos PT, Pappa V, Viniou NA, Kourakli A, Τsokanas D, Vassilakopoulos TP, Hatzimichael E, Bouronikou E, Ximeri M, Pontikoglou C, Megalakaki A, Zikos P, Panayiotidis P, Dimou M, Karakatsanis S, Papaioannou M, Vardi A, Kontopidou F, Harchalakis N, Adamopoulos I, Symeonidis A, Kotsianidis I. Liapis K, et al. Among authors: kourakli a. Blood Cancer J. 2021 Feb 11;11(2):30. doi: 10.1038/s41408-021-00424-4. Blood Cancer J. 2021. PMID: 33574231 Free PMC article. No abstract available.
Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
Diamantopoulos PT, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Gogos D, Karakatsanis S, Papadaki H, Palla A, Hatzimichael E, Dimou M, Papageorgiou S, Delimpasis S, Papaioannou M, Papoutselis M, Kourakli A, Tsokanas D, Anagnostopoulos A, Kontos CK, Panayiotidis P, Viniou NA; Hellenic MDS study group. Diamantopoulos PT, et al. Among authors: kourakli a. Leuk Lymphoma. 2019 Jul;60(7):1721-1730. doi: 10.1080/10428194.2018.1540783. Epub 2018 Nov 14. Leuk Lymphoma. 2019. PMID: 30424699
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.
Terpos E, Katodritou E, Symeonidis A, Zagouri F, Gerofotis A, Christopoulou G, Gavriatopoulou M, Christoulas D, Ntanasis-Stathopoulos I, Kourakli A, Konstantinidou P, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: kourakli a. Int J Cancer. 2019 Jul 15;145(2):559-568. doi: 10.1002/ijc.32125. Epub 2019 Jan 22. Int J Cancer. 2019. PMID: 30650184 Free article. Clinical Trial.
Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Diamantopoulos PT, Kontandreopoulou CN, Symeonidis A, Kotsianidis I, Pappa V, Galanopoulos A, Vassilakopoulos T, Dimou M, Solomou E, Kyrtsonis MC, Siakantaris M, Angelopoulou M, Kourakli A, Papageorgiou S, Christopoulou G, Roumelioti M, Panayiotidis P, Viniou NA; Hellenic MDS Study Group. Diamantopoulos PT, et al. Among authors: kourakli a. Ann Hematol. 2019 Jun;98(6):1383-1392. doi: 10.1007/s00277-019-03650-w. Epub 2019 Mar 15. Ann Hematol. 2019. PMID: 30877373
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.
Diamantopoulos P, Koumbi D, Kotsianidis I, Pappa V, Symeonidis A, Galanopoulos A, Zikos P, Papadaki HA, Panayiotidis P, Dimou M, Hatzimichael E, Vassilopoulos G, Delimpasis S, Mparmparousi D, Papageorgiou S, Variami E, Kyrtsonis MC, Megalakaki A, Kotsopoulou M, Repousis P, Adamopoulos I, Kontopidou F, Christoulas D, Kourakli A, Tsokanas D, Konstantinos Papoutselis M, Kyriakakis G, Viniou NA; Hellenic MDS study group. Diamantopoulos P, et al. Among authors: kourakli a. Cancer Med. 2019 May;8(5):2056-2063. doi: 10.1002/cam4.2090. Epub 2019 Mar 21. Cancer Med. 2019. PMID: 30897290 Free PMC article.
Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS).
Kotsianidis I, Papageorgiou SG, Pappa V, Galanopoulos AG, Viniou NA, Vassilakopoulos TP, Papoutselis M, Vrachiolias G, Papadopoulos V, Diamantopoulos PT, Tsokanas D, Kourakli A, Symeonidis A. Kotsianidis I, et al. Among authors: kourakli a. Mediterr J Hematol Infect Dis. 2019 Jul 1;11(1):e2019045. doi: 10.4084/MJHID.2019.045. eCollection 2019. Mediterr J Hematol Infect Dis. 2019. PMID: 31308921 Free PMC article. No abstract available.
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry.
Diamantopoulos PT, Pappa V, Symeonidis A, Kotsianidis I, Galanopoulos A, Papadaki H, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Kotsopoulou M, Repousis P, Dimou M, Solomou E, Pontikoglou C, Kyriakakis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Panayiotidis P, Viniou NA. Diamantopoulos PT, et al. Among authors: kourakli a. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):114-121. doi: 10.1016/j.clml.2019.09.614. Epub 2019 Sep 28. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31884152
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Papadopoulos V, Diamantopoulos PT, Papageorgiou SG, Papoutselis M, Vrachiolias G, Pappa V, Galanopoulos AG, Vassilakopoulos TP, Hatzimichael E, Zikos P, Papadaki HA, Bouchla A, Panayiotidis P, Megalakaki A, Papaioannou M, Liapis K, Dryllis G, Tsokanas D, Kourakli A, Symeonidis A, Viniou NA, Kotsianidis I. Papadopoulos V, et al. Among authors: kourakli a. Hematol Oncol. 2020 Oct;38(4):541-553. doi: 10.1002/hon.2756. Epub 2020 Jun 26. Hematol Oncol. 2020. PMID: 32495951
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.
Diamantopoulos PT, Symeonidis A, Pappa V, Kotsianidis I, Galanopoulos A, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Repousis P, Kotsopoulou M, Dimou M, Solomou E, Dryllis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kyrtshonis MC, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA. Diamantopoulos PT, et al. Among authors: kourakli a. Br J Haematol. 2021 Mar;192(6):978-987. doi: 10.1111/bjh.17062. Epub 2020 Aug 30. Br J Haematol. 2021. PMID: 32862447 Free article.
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
Papageorgiou SG, Kotsianidis I, Bouchla A, Symeonidis A, Galanopoulos A, Viniou NA, Hatzimichael E, Vassilakopoulos TP, Gogos D, Megalakaki A, Zikos P, Diamantopoulos P, Kourakli A, Giannoulia P, Papoutselis M, Poulakidas E, Arapaki M, Vardi A, Anagnostopoulos A, Mparmparousi D, Papaioannou M, Bouronikou E, Dimou M, Papadaki H, Panayiotidis P, Pappa V. Papageorgiou SG, et al. Among authors: kourakli a. Ther Adv Hematol. 2020 Dec 8;11:2040620720966121. doi: 10.1177/2040620720966121. eCollection 2020. Ther Adv Hematol. 2020. PMID: 33343854 Free PMC article.
62 results